您有罹患大肠癌的风险吗？在 1 分钟内回答这 13 个问题，就能知道答案。
我们的 "临床试验搜索器"（Clinical Trial Finder）是为晚期 CRC 患者查找和了解更多具有影响力的研究的一站式平台。目前的数据适用于同时具有 MSS 和 MSI-H 状态的 IV 期转移性患者。
我们的 "治愈之路 "报告是我们对未来的计划。这个计划不仅仅是为抗击癌症协会制定的，也是为每一个愿意支持这项事业的人制定的。
在我们的网上商店购物，无论你走到哪里都能提高人们的意识从T恤衫和腰包到病人教育资源，我们什么都有。
提高认识。成为一个倡导者。举办一个活动。
计划状况 临床试验的病人招募情况
阶段 正在招募的临床试验阶段（I、II或III）。
以免疫疗法为中心的试验 表示试验是否为免疫治疗试验的标志
允许先前的免疫治疗 临床试验是否对之前接受过免疫治疗的患者开放
由CRC指导的试验 表示试验是否专门针对结肠癌、直肠癌或大肠癌患者的标志。
药品 临床试验中使用的治疗药物
标签
评论
针对 MSS CRC 的 III 期试验，其中一臂包括免疫疗法。 Relatlimab（抗 LAG-3 抗体，免疫疗法）联合 nivolumab（抗 PD-1，免疫疗法，Opdivo）与标准疗法（Stivarga 或 Lonsurf）对比，用于治疗既往接受过至少 1 种但不超过 4 种疗法失败的 MSS mCRC 晚期患者。 试验采用随机分配法（患者可被分配到两组中的任何一组）。 之前未接受过免疫疗法、瑞戈非尼或 TAS-102 治疗。
抗LAG-3抗体relatlimab与抗PD-1联合使用，对抗PD-1单药治疗耐药的黑色素瘤患者产生了临床活性。
纳入标准
Histological confirmed previously treated colorectal cancer with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry.
Participants must have:.
i) progressed during or within approximately 3 months following the last administration of approved standard therapies (at least 1, but not more than 4 prior lines of therapies in the metastatic setting), which must include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, and anti-EGFR therapy (if RAS wild-type), if available in the respective country, or;.
ii) been intolerant to prior systemic chemotherapy regimens if there is documented evidence of clinically significant intolerance despite adequate supportive measures.
Must have sufficient tumor tissue & evaluable PD-L1 expression to meet the study requirements. Must have measurable disease per RECIST v1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately.
排除标准
Prior treatment with either an immunotherapy or with regorafenib or with TAS-102. Untreated central nervous system (CNS) metastases, participants are eligible if CNS metastases have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment). History of refractory hypertension not controlled with anti-hypertensive therapy, myocarditis (regardless of etiology), uncontrolled arrhythmias, acute coronary syndrome within 6 months prior to dosing, Class II congestive heart failure (as per the New York Heart Association Functional Classification), interstitial lung disease/pneumonitis or an active, known or suspected autoimmune disease. 根据当地标准检测，确认肿瘤微卫星不稳定性高/错配修复缺陷（MSI-H/dMMR）状态；可接受初次诊断时的 MSI/MMR 检测结果。 Other protocol-defined Inclusion/Exclusion criteria apply.
NCT ID 来自clinicaltrials.gov或其他数据库的试验ID号
添加审判日期 临床试验被添加到clinicaltrials.gov网站的日期
更新日期 临床试验在clinicaltrials.gov网站上更新的日期